

For Action: Assistant Director Integrated Care, Head of Pharmacy and Medicines Management, Strategic Planning and Performance Group & BSO
Heads of Pharmacy and Medicines Management of HSC Trusts
Regulation Quality Improvement Authority

From: Chief Pharmaceutical Officer
Professor Cathy Harrison
Castle Buildings
Upper Newtownards Road
Belfast BT4 3SQ

Telephone: 028 90 523219
Facsimile: 028 90 522335

E-Mail: cathy.harrison@health-ni.gov.uk

Our Ref: PHC/05/2024
Date: 14 February 2024

UPDATED MEDICINES RECALL

CLASS 3 MEDICINES RECALL

Action Within 5 Days

Pharmacy/Wholesaler Level Recall

Torrent Pharma (UK) Limited

Ramipril 1.25mg tablets

PL 36687/0222

SNOMED Code 36834211000001109

Batch No	Expiry Date	Pack Size	First Distributed
MG21264	29/02/2024	28 tablets	13/12/2021
MG21334	31/03/2024	28 tablets	30/03/2022
MG21335	31/03/2024	28 tablets	26/05/2022
MG221014	30/11/2025	28 tablets	22/03/2023
MG221016	30/11/2025	28 tablets	16/05/2023
MG23488	30/04/2026	28 tablets	25/08/2023
MG23489	30/04/2026	28 tablets	12/09/2023
MG23490	30/04/2026	28 tablets	12/10/2023
MG23729	30/06/2026	28 tablets	05/12/2023

Active Pharmaceutical Ingredient: Ramipril

Brief description of the problem

Torrent Pharma (UK) Limited is recalling the above batches of Ramipril 1.25mg tablets as a precautionary measure due to these batches having a low assay and high related substances test results after their release to the market.

Advice for healthcare professionals

Stop supplying the above batches immediately. Quarantine all remaining stock and return it to your supplier using your supplier's approved process.

Advice for patients

No action is required by patients as this is a Pharmacy and Wholesaler level recall. Patients should continue to take medicines from these batches as prescribed by your healthcare professional. The specified batches are being recalled as a precautionary measure and are unlikely to cause harm if taken.

Patients who experience adverse reactions or have any questions about the medication should seek medical attention. Any suspected adverse reactions should also be reported via the [MHRA Yellow Card scheme](#).

Further Information


For medical information enquiries please contact APCER Life Sciences, via telephone: 0800 0885366, or email: Medinfo.Torrent@apcerls.com

For stock control enquiries please contact the Torrent Pharma (UK) Limited Customer Service & Sales Executive via telephone: 01293 574188, or email: luke.davies@torrentpharma.co.uk or [priti.pragji@torrentpharma.co.uk](mailto:pritti.pragji@torrentpharma.co.uk)

Recipients of this Medicines Recall should bring it to the attention of relevant contacts by copy of this notice. RQIA should bring this information to the attention of private hospitals/clinics registered with them and any other relevant care facilities.

The Business Services Organisation is asked to bring this information to the attention of Community Pharmacists and General Medical Practitioners directly.

Yours sincerely

A handwritten signature in black ink, appearing to read "Cathy Harrison", written on a light yellow rectangular background.

Professor Cathy Harrison
Chief Pharmaceutical Officer